BRIEF published on 08/08/2024 at 22:20, 3 months 12 days ago Nanobiotix: Information on Voting Rights and Shares as of July 31, 2024 Share Capital Voting Rights Actions Sotck Exchange NANOBIOTIX
PRESS RELEASE published on 08/08/2024 at 22:15, 3 months 12 days ago Voting Rights and Shares Capital of the Company Nanobiotix announces monthly publication of voting rights and shares capital in compliance with French Commercial Code. Learn more about the company's disruptive biotechnology approaches Voting Rights French Commercial Code Biotechnology Shares Capital NANOBIOTIX
BRIEF published on 07/09/2024 at 22:20, 4 months 11 days ago Voting Rights and Shares Capital of Nanobiotix Voting Rights Shares Euronext Nasdaq NANOBIOTIX
PRESS RELEASE published on 07/09/2024 at 22:15, 4 months 11 days ago Voting Rights and Shares Capital of the Company Nanobiotix discloses voting rights and shares capital information as per French Commercial Code. Check the latest figures for June 30, 2024 Euronext Paris Voting Rights French Commercial Code Shares Capital NANOBIOTIX
BRIEF published on 07/03/2024 at 15:54, 4 months 17 days ago Threshold crossings at NANOBIOTIX by Goldman Sachs Group AMF Goldman Sachs NANOBIOTIX Threshold Crossings
BRIEF published on 06/12/2024 at 22:20, 5 months 8 days ago Nanobiotix hosts virtual discussion on the potential of NBTXR3 in cancer treatments Immunotherapy Head And Neck Cancer NANOBIOTIX NBTXR3 Virtual Discussion
PRESS RELEASE published on 06/12/2024 at 22:15, 5 months 8 days ago NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 Nanobiotix to host virtual KOL event discussing NBTXR3 combined with immunotherapy in head and neck cancer and beyond on June 18, 2024 Immunotherapy Head And Neck Cancer NANOBIOTIX NBTXR3 Virtual KOL Event
BRIEF published on 06/11/2024 at 22:20, 5 months 9 days ago Nanobiotix: Monthly Information on Voting Rights and Shares Voting Rights Euronext Actions Nasdaq NANOBIOTIX
PRESS RELEASE published on 06/11/2024 at 22:15, 5 months 9 days ago Voting Rights and Shares Capital of the Company Nanobiotix discloses its voting rights and shares capital information as of May 31, 2024, in compliance with regulatory requirements. The company is a clinical biotechnology firm listed on Euronext Paris and Nasdaq Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 06/02/2024 at 16:05, 5 months 18 days ago Nanobiotix Announces Promising Data on NBTXR3 for Head and Neck Cancer Patients Clinical Trial Head And Neck Cancer NANOBIOTIX NBTXR3 ASCO
Published on 11/21/2024 at 13:30, 23 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 23 minutes ago Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 53 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 53 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 53 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 12:35, 1 hour 18 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 38 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 6 hours 55 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 33 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 8 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 8 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
